JPRN-UMIN000001995已完成未知
Randomized Parallel Group Phase II Clinical Study of Sorafenib/Interferon Combination Therapy and Sunitinib Monotherapy for Advanced Renal Cell Carcinoma - Comparative Study of Sorafenib/IFN Combination Therapy and Sunitinib Monotherapy for Advanced RCC
Osaka Urological Oncology Research Group0 个研究点目标入组 200 人开始时间: 2009年5月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who have received systemic therapy for renal carcinoma 2.Patients who completed the surgery or radiotherapy for renal carcinoma less than 4 weeks before initiation of the present study 3.Patients suffering from multiple cancers within last 5 years, excepting those who received appropriate treatment for the following a. Basal cell carcinoma or squamous cell carcinoma of skin b. Uterine cervix carcinoma, gastric cancer or large intestine carcinoma (in situ) 4. Patients who are diagnosed as having cerebral metastasis, meningeal metastasis, spinal cord compression, or meningitis carcinomatosa 5. Patients who are found to have either of the following diseases within 12 months before initiation of the present study Myocardial infarction, severe or unstable angina, coronary or peripheral arterial bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism 6. Patients with arrhythmia (Grade 2 or severer according to the CTCAE ver. 3.0) or atrial fibrillation (regardless of Gragde), or male patients with QTc interval prolonged over 450 msec or female patients with QTc interval prolonged over 470 msec
研究者
相似试验
进行中（未招募）
不适用
A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsuled [150 or 220 mg once daily strating wiht half dose (i.e. 75 or 110 mg)on the day of surgery] compared to subcutaneous enoxaparin 40 mg once daily for 28-35 days, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery.Prevention of venous thromboembolism following primary elective total hip replacement surgeryMedDRA version: 6.1Level: SOCClassification code 10005329EUCTR2004-001988-21-ITBOEHRINGER ING.
尚未招募
不适用
Management of Psoriasis with Kushtanashana rasa and Kutaja suryapaki taila -A clinical studyCTRI/2020/03/024089Dr Supreetha M
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-DEKeyNeurotek Pharmaceuticals AG108
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-CZKeyNeurotek Pharmaceuticals AG108
进行中（未招募）
不适用
A double-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-BEKeyNeurotek Pharmaceuticals AG108